Osteocalcin promoter-based toxic gene therapy
CA 2291262 A1 · Owner: Ko, Song-Chu · Inventors: Ko, Song-Chu; Kao, Chinghai; Chung, Leland W.K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered directly or systemically (intravascularly) to treat metastatic cancer, including osteosarcoma, breast cancer prostate cancer, ocular , melanoma or brain cancer. Systemic administration of this agent provides a preferred route over local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions including , benign prostatic hypertrophy and arteriosclerosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 21, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 21, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 21, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.